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cardial infarction, chest pain greater than 20 minutes and
irregular specifications of EKG. The outcome measured
was reduction in mortality at a 30-day follow-up. The
study was based on a societal perspective, hence the cost
measure included both direct costs such as cost of hospi-
talizations, drug acquisition, follow-up hospitalizations
and physicians’ fees, and indirect costs. We calculated the
effectiveness measure, using life expectancy, as number of
quality-adjusted life-years (QALYs) saved.
RESULTS: The expected total costs of t-PA treatment
were $16,885 and with streptokinase, the expected total
costs were $14,472. The number of QALYs saved for
each therapy were 12.379 years for t-PA and 12.16 years
for streptokinase. The ICE ratio was calculated to be
$11,171 per QALY.
CONCLUSION: Since the ICE ratio of $11,171/QALY is
less than the most popular cut-off ratio of $40,000/QALY,
we concluded that t-PA is more cost-effective than strep-
tokinase in the treatment of acute myocardial infarctions.
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OBJECTIVE: To examine the costs and outcomes associ-
ated with the use of valsartan, an angiotensin II receptor
blocker, compared to six different anti-hypertensive med-
ications as second-line treatment for mild to moderate
hypertension over 12 months.
METHODS: A decision analytic model was developed to
evaluate the costs and outcomes associated with initiating
treatment with seven different anti-hypertensive medica-
tions. A combination of meta-analysis and predictive logis-
tic regression analysis was used to model effectiveness de-
fined as the proportion of patients responding to anti-
hypertensive treatment (response was defined as a reduction
of diastolic blood pressure to below 90 mmHg or a reduc-
tion of greater than 10 mmHg). The meta-analysis was per-
formed on an intent-to-treat basis. Two regression analyses
were used, one to impute a response rate for those studies
where only change in blood pressure was reported and a
second to determine a dose-response relationship for each
comparator. Costs for drugs, laboratory tests, and physician
visits were obtained from publicly available Ontario
sources. The analysis determined the cost per successful re-
sponder at 12 months for each initial comparator.
RESULTS: The analysis demonstrated that treatment
patterns associated with each medication, particularly
laboratory tests, played an important role in the overall
cost and cost-effectiveness of each therapy as opposed to
simply the drug acquisition cost.
CONCLUSIONS: At least two drugs from each class, an-
giotensin receptor blocker, angiotensin converting en-
zyme inhibitor, and calcium channel blocker, were evalu-
ated and no evidence of class effects was seen.
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OBJECTIVE: Determine current clinical practice in the
treatment of mild-to-moderate uncomplicated hyperten-
sion.
METHODS: Delphi panel survey of general practitioners
and cardiologists in the United States. First round: 11
physician responders. Second round: 10 of 11 physicians
responded. Consensus reached in the second round.
Questions addressed the status quo, JNC-VI guidelines,
initial therapy, and second-line therapy.
RESULTS: Diuretics and ACE inhibitors are more fre-
quently prescribed than other drug classes. HCTZ is the
most frequently used diuretic, atenolol and metoprolol
are the most frequently used beta-blockers. A variety of
drugs are prescribed from ACE inhibitors, calcium chan-
nel blockers and angiotensin-II inhibitors. When a pa-
tient is given combination therapy, the second agent is
typically a diuretic. Physicians generally agreed with the
JNC-VI guidelines, except that: 1) more drugs should be
permissible as first-line therapy (seven physicians regu-
larly consider classes other than diuretics or beta-block-
ers as initial therapy), and 2) comorbidities are a major
factor in drug choice and the guidelines do not ade-
quately address this. Follow-up after initiating drug ther-
apy typically occurs at 1 month. New therapies will gen-
erally be titrated upward once or twice (depending on the
drug) before the drug is discontinued due to lack of effi-
cacy. Once a patient’s hypertension is controlled, moni-
toring occurs every 3 to 4 months. It is extremely rare for
a patient to be unresponsive to all five drug classes. Re-
sults from a series of case studies in which physicians
were asked to select the class of medication they would
prescribe depending on the patient’s age, gender, initial
blood pressure, and initial therapy will be presented.
CONCLUSIONS: This study gives researchers insights
into the differences between clinical practice and clinical
guidelines in hypertension treatment.
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OBJECTIVE: The aim of this study was to determine
concurrence of administrative claims data and medical
records abstraction data with regard to selected comor-
bid conditions among hypertensive subjects.
METHODS: Study subjects were incident hypertensives
identified by: 1) at least one claim with an ICD-9 diagno-
sis code of hypertension and at least one claim for an
anti-hypertensive drug; or 2) at least two claims with an
ICD-9 diagnosis code of hypertension, preceded by at
least 6 months of health plan enrollment free of anti-
hypertensive prescriptions. Nurse abstractors reviewed
medical records for documentation of seven comorbid
conditions, including ischemic heart disease, congestive
heart failure, chronic renal failure, cerebrovascular dis-
ease, complicated hypertension, hyperlipidemia, and dia-
betes. To determine whether comorbidities noted in med-
ical records data appeared in claims data, we reviewed
physician, facility, and pharmacy claims for a 12-month
period after the initial hypertension indicator to identify
ICD-9 diagnosis codes, CPT procedure codes, or pre-
scriptions for drugs of interest.
RESULTS: 118 subjects were included in the analysis.
Claims and medical records data, respectively, identified
ischemic heart disease (14 of 15); congestive heart failure
(7 of 10); chronic renal failure (0 of 1); cerebrovascular
disease (3 of 1); complicated hypertension (18 of 3); hy-
perlipidemia (44 of 73); and diabetes (25 of 18).
CONCLUSION: The extent to which claims data identi-
fied comorbidities compared to medical records data var-
ied greatly by comorbid condition. Some of this variation
may be due to limitations of medical records and claims
data, including: 1) subjects may have seen additional phy-
sicians whose records were not abstracted, but subjects’
comorbidities were in claims data; 2) medical records may
not contain a patient’s diagnosis, but pharmacy claims
contain therapies; and 3) claims data may not identify
chronic conditions if a patient is not receiving therapy.
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Confounding by indication may account for the observed
elevated risk of acute myocardial infarction in hyperten-
sives treated with calcium antagonists (CA). If CAs are
preferentially prescribed for sicker patients, then in-
creased risk of adverse events is due partly to the underly-
ing disease, not the medication.
OBJECTIVE: To test the hypothesis that confounding by
indication occurs.
METHODS: Pennsylvania Medicaid claims data were
used to conduct a retrospective cohort analysis of hyper-
tensive enrollees who received anti-hypertensive mono-
therapy. Diagnoses of 12 known cardiovascular risk fac-
tors recorded on medical claims 7 days or less prior to
the start of anti-hypertensive drug therapy were exam-
ined. Logistic regression analysis was performed to evalu-
ate the association between each prior diagnosis and sub-
sequent CA use, controlling for demographic variables
and other relevant diagnoses. Since CA use was not rare,
we approximated the risk ratio (RR) from the adjusted
odd ratio using the formula: RR  OR/(1  P)  (P 
OR) where P is the non-exposed group.
RESULTS: CAs were prescribed significantly more often
than other monotherapy for patients with prior diag-
noses of: arteriosclerotic cardiovascular disease (RR 
3.06; 95% CI 1.96–3.82); angina (RR  2.03; 95% CI
1.51–2.58); COPD (RR  1.76; 95% CI 1.14–2.45); dia-
betes (RR  1.34; 95% CI 1.06–1.66); and ischemic
heart disease (RR  1.61; 95% CI 1.07–2.25).
CONCLUSION: There is strong evidence that confound-
ing by indication occurred in this population. Findings of
adverse outcomes based on observational studies of CA
therapy may arise from unrecognized confounding. This
possibility should be considered in the design of observa-
tional pharmacotherapy outcomes studies.
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Guidelines for the evaluation and management of heart
failure recommend different drug therapies for congestive
heart failure (CHF) patients with left-ventricular (LV)
systolic dysfunction versus those with normal LV systolic
function (LVERSUSF). To what extent these guidelines
are translated into differing prescribing in actual practice
is unknown.
OBJECTIVE: To compare drug utilization in hospitalized
CHF patients with and without LV systolic dysfunction.
METHODS: Medical records were reviewed for all patients
with a principal discharge diagnosis of CHF from January 1
through June 30, 1997 at an urban public hospital (N 
387). LVERSUSF assessments performed within 6 months
before discharge were used to classify LVERSUSF. Pre-
scribed drug therapies were determined at discharge.
RESULTS: Of 207 patients with LV systolic dysfunction,
161 (81.0%) patients were discharged on an angiotensin-
converting enzyme (ACE) inhibitor, versus 66 (71.0%) of
93 patients with normal LVERSUSF (p  0.05). After ex-
cluding patients with contraindications of ACE inhibitor
use, the difference in ACE inhibitor use between the pa-
tients with and without LV systolic dysfunction was not
significant (p  0.09). No statistically significant differ-
ences were observed between patients with and without
LV systolic dysfunction regarding the utilization of di-
uretics (90.0% versus 91.0%), beta blockers (3.0% ver-
sus 4.0%), and alpha blockers (4.0% versus 6.0%).
